Cancer Genetics, Inc. and Lantern Pharma announce strategic collaboration
Cancer Genetics announced a strategic collaboration with Lantern Pharma, a clinical-stage company developing molecularly-targeted precision oncology compounds for treatment of cancer. CGIX will collaborate on biomarker discovery, clinical trials and genomics projects for Lantern’s lead candidates. January 17, 2017